The present application relates generally to devices, application systems and methods for removing heat from subcutaneous lipid-rich cells. In particular, several embodiments are directed toward a device that provides independent control of the heat flux through a plurality of zones based on a desired heat flux profile.
Excess body fat, or adipose tissue, may be present in various locations of the body, including, for example, the thigh, buttocks, abdomen, knees, back, face, arms, chin, and other areas. Moreover, excess adipose tissue is thought to magnify the unattractive appearance of cellulite, which forms when subcutaneous fat protrudes into the dermis and creates dimples where the skin is attached to underlying structural fibrous strands. Cellulite and excessive amounts of adipose tissue are often considered to be unappealing. Moreover, significant health risks may be associated with higher amounts of excess body fat.
A variety of methods have been used to treat individuals having excess body fat and, in many instances, non-invasive removal of excess subcutaneous adipose tissue can eliminate unnecessary recovery time and discomfort associated with invasive procedures such as liposuction. Conventional non-invasive treatments for removing excess body fat typically include topical agents, weight-loss drugs, regular exercise, dieting or a combination of these treatments. One drawback of these treatments is that they may not be effective or even possible under certain circumstances. For example, when a person is physically injured or ill, regular exercise may not be an option. Similarly, weight-loss drugs or topical agents are not an option when they cause an allergic or negative reaction. Furthermore, fat loss in selective areas of a person's body often cannot be achieved using general or systemic weight-loss methods.
Other methods designed to reduce subcutaneous adipose tissue include laser-assisted liposuction and mesotherapy. Newer non-invasive methods include applying radiant energy to subcutaneous lipid-rich cells via, e.g., radio frequency and/or light energy, such as described in U.S. Patent Publication No. 2006/0036300 and U.S. Pat. No. 5,143,063, or via, e.g., high intensity focused ultrasound (HIFU) radiation such as described in U.S. Pat. Nos. 7,258,674 and 7,347,855. In contrast, methods and devices for non-invasively reducing subcutaneous adipose tissue by cooling are disclosed in U.S. Pat. No. 7,367,341 entitled “METHODS AND DEVICES FOR SELECTIVE DISRUPTION OF FATTY TISSUE BY CONTROLLED COOLING” to Anderson et al. and U.S. Patent Publication No. 2005/0251120 entitled “METHODS AND DEVICES FOR DETECTION AND CONTROL OF SELECTIVE DISRUPTION OF FATTY TISSUE BY CONTROLLED COOLING” to Anderson et al., the entire disclosures of which are incorporated herein by reference.
In the drawings, identical reference numbers identify similar elements or acts. The sizes and relative positions of elements in the drawings are not necessarily drawn to scale. For example, the shapes of various elements and angles are not necessarily drawn to scale, and some of these elements are arbitrarily enlarged and positioned to improve drawing legibility. Further, the particular shapes of the elements as drawn are not necessarily intended to convey any information regarding the actual shape of the particular elements, and are generally selected for ease of recognition in the drawings.
Overview
Several examples of devices, application systems and methods for independently controlling the heat flux through a plurality of cooling zones for cooling subcutaneous adipose tissue in accordance with the technology are described below. Although the following description provides many specific details of the following examples in a manner sufficient to enable a person skilled in the relevant art to practice, make and use them, several of the details and advantages described below may not be necessary to practice certain examples and methods of the technology. Additionally, the technology may include other examples and methods that are within the scope of the claims but are not described in detail.
Reference throughout this specification to “one example,” “an example,” “one embodiment” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the example is included in at least one example of the present technology. Thus, the occurrences of the phrases “in one example,” “in an example,” “one embodiment” or “an embodiment” in various places throughout this specification are not necessarily all referring to the same example. Furthermore, the particular features, structures, routines, steps or characteristics may be combined in any suitable manner in one or more examples of the technology. The headings provided herein are for convenience only and are not intended to limit or interpret the scope or meaning of the claimed technology.
One embodiment of an application system for cooling subcutaneous lipid-rich tissue comprises a cooling unit, a cryoprotectant vessel, a contact member and an array of selectably addressable heating elements. The cryoprotectant vessel is configured to contain a fluidic cryoprotectant such that at least a portion of the cryoprotectant is cooled by the cooling unit to a desired base temperature. The contact member is attached to the cryoprotectant vessel, and the contact member includes a backside in contact with the cryoprotectant and a front side opposite the backside. The contact member is configured to allow the cryoprotectant to flow from the backside to the front side, and the array of selectably addressable heating elements is carried by the contact member.
One embodiment of a method of operating an application system for cooling subcutaneous lipid-rich tissue includes cooling a cryoprotectant to a base temperature below 37° C. The method further includes passing the cyroprotectant through a flexible contact member of an interface element, and selectively heating at least one heating element of an array of heating elements carried by the flexible contact member to a temperature different than other heating elements of the array. As a result, the temperature of the cryoprotectant proximate to the heated heating element is raised to a contact temperature higher than the base temperature.
In a more detailed embodiment of an application system for cooling subcutaneous lipid-rich tissue, the cooling unit comprises a heat exchanger having a coolant chamber through which a coolant can flow. The cryoprotectant vessel comprises a back panel and a sidewall projecting from the back panel. The contact member is a flexible barrier attached to the sidewall of the cryoprotectant vessel to form a cryoprotectant chamber, and the flexible barrier and the cryoprotectant vessel together form a disposable interface element. The flexible barrier, for example, can be a porous membrane or other flexible panel with small holes. The interface assembly further comprises a connector that couples the cryoprotectant vessel to the cooling unit. The application system of this embodiment further comprises an array of temperature sensor sets carried by the flexible membrane, and each individual heating element is associated with a corresponding temperature sensor set. Additionally, the application system can optionally comprise a larger heating element spaced apart from the backside of the array of temperature sensor sets and a controller. The controller includes a computer-operable medium programmed to receive sensed temperatures from the temperature sensor sets and adjust the associated heating elements based on the sensed temperatures and a desired heating profile to thereby provide localized temperature differentials in the cryoprotectant corresponding to the desired heating profile.
General System Components
The treatment system 10 is suitable for cooling the subcutaneous adipose tissue of a subject 11 in a manner that reduces the volume of the adipose tissue. “Subcutaneous tissue” can include tissue lying beneath the dermis and includes subcutaneous fat, or adipose tissue that may be composed primarily of lipid-rich cells, or adipocytes. When cooling subcutaneous tissues to a temperature lower than 37° C., subcutaneous lipid-rich cells can be affected selectively. In general, the epidermis and dermis of the subject 11 lack lipid-rich cells compared to the underlying lipid-rich cells forming the adipose tissue. Because non-lipid-rich cells usually can withstand colder temperatures better than lipid-rich cells, the subcutaneous lipid-rich cells can be affected selectively without affecting the non-lipid-rich cells in the dermis, epidermis and other surrounding tissue. In some embodiments, the treatment system 100 can apply cooling temperatures to the skin of the subject 11 in a range of about −20° C. to about 20° C. In other embodiments, the cooling temperatures can be from about −20° C. to about 10° C., approximately 0° C. to approximately 20° C., about −15° C. to about 5° C., approximately −5° C. to approximately 15° C., or about −10° C. to about 0° C.
Without being bound by theory, the selective effect of cooling on lipid-rich cells is believed to result in, for example, membrane disruption, cell shrinkage, disabling, destroying, removing, killing or other methods of lipid-rich cell alteration. Such alteration is believed to stem from one or more mechanisms acting alone or in combination. It is thought that such mechanism(s) trigger an apoptotic cascade, which is believed to be the dominant form of lipid-rich cell death by non-invasive cooling.
Apoptosis, also referred to as “programmed cell death”, is a genetically-induced death mechanism by which cells self-destruct without incurring damage to surrounding tissues. An ordered series of biochemical events induce cells to morphologically change. These changes include cellular blebbing, loss of cell membrane asymmetry and attachment, cell shrinkage, chromatin condensation and chromosomal DNA fragmentation. Injury via an external stimulus, such as cold exposure, is one mechanism that can induce cellular apoptosis in cells. Nagle, W. A., Soloff, B. L., Moss, A. J. Jr., Henle, K. J. “Cultured Chinese Hamster Cells Undergo Apoptosis After Exposure to Cold but Nonfreezing Temperatures” Cryobiology 27, 439-451 (1990).
One aspect of apoptosis, in contrast to cellular necrosis (a traumatic form of cell death causing local inflammation), is that apoptotic cells express and display phagocytic markers on the surface of the cell membrane, thus marking the cells for phagocytosis by macrophages. As a result, phagocytes can engulf and remove the dying cells (e.g., the lipid-rich cells) without eliciting an immune response. Temperatures that elicit these apoptotic events in lipid-rich cells may contribute to long-lasting and/or permanent reduction and reshaping of subcutaneous adipose tissue.
One mechanism of apoptotic lipid-rich cell death by cooling is believed to involve localized crystallization of lipids within the adipocytes at temperatures that do not induce crystallization in non-lipid-rich cells. The crystallized lipids selectively may injure these cells, inducing apoptosis (and may also induce necrotic death if the crystallized lipids damage or rupture the bi-lipid membrane of the adipocyte). Another mechanism of injury involves the lipid phase transition of those lipids within the cell's bi-lipid membrane, which results in membrane disruption, thereby inducing apoptosis. This mechanism is well-documented for many cell types and may be active when adipocytes, or lipid-rich cells, are cooled. Mazur, P., “Cryobiology: the Freezing of Biological Systems” Science, 68: 939-949 (1970); Quinn, P. J., “A Lipid Phase Separation Model of Low Temperature Damage to Biological Membranes” Cryobiology, 22: 128-147 (1985); Rubinsky, B., “Principles of Low Temperature Preservation” Heart Failure Reviews, 8, 277-284 (2003). Other yet-to-be understood apoptotic mechanisms may exist, based on the relative sensitivity of lipid-rich cells to cooling compared to non-lipid rich cells.
In addition to the apoptotic mechanisms involved in lipid-rich cell death, local cold exposure also is believed to induce lipolysis (i.e., fat metabolism) of lipid-rich cells and has been shown to enhance existing lipolysis which serves to further increase the reduction in subcutaneous lipid-rich cells. Vallerand, A. L., Zamecnik. J., Jones, P. J. H., Jacobs, I. “Cold Stress Increases Lipolysis, FFA Ra and TG/FFA Cycling in Humans” Aviation, Space and Environmental Medicine 70, 42-50 (1999).
In various embodiments, the treatment system 10 includes a controller, a computing device, a data acquisition device, a chiller, and one or more treatment devices. These components can be implemented in various embodiments to apply selected treatment profiles to a subject 11 (e.g., a human or animal) for reducing adipose tissue.
In the embodiment illustrated in
The cooling unit 15 can be a component of a cooling unit integrated with the treatment device 14, and the cooling unit 15 may include one or more Peltier-type thermoelectric elements, such as a plurality of individually controlled thermal segments that create a custom spatial cooling profile and/or a time-varying cooling profile. Each custom treatment profile can include one or more segments, and each segment can include a specified duration, a target temperature, and control parameters for features such as vibration, massage, vacuum and other treatment modes. Cooling devices having multiple individually controlled heat exchanging units are described, e.g., in commonly assigned U.S. Patent Publication No. 2008/0077211.
The treatment unit 16 may be a refrigeration unit, a cooling tower, a thermoelectric chiller or cooler or any other device or cooling unit capable of removing heat from a coolant in addition to or in lieu of the cooling unit 15 at the treatment device. The treatment unit 16 can be operatively coupled to the treatment device 14 by supply and return fluid lines 18a and 18b that circulate chilled fluid (e.g., a coolant) through the treatment device 14. Alternatively, the treatment unit 16 can circulate warm fluid to the treatment device 14 during periods of warming. Examples of the circulating coolant include water, glycol, synthetic heat transfer fluid, oil, a refrigerant, a cryoprotectant and/or any other suitable heat-conducting fluid. The fluid lines 18a and 18b may be hoses or other conduits constructed from polyethylene, polyvinyl chloride, polyurethane and/or other materials that can accommodate the particular circulating coolant. Furthermore, one skilled in the art will recognize that there are a number of other cooling technologies that could be used such that the cooling units or coolers of the treatment unit 16 or the treatment device 14 need not be limited to those described herein.
The system 10 may further include a power supply 20 and a processing unit 24 operatively coupled to the treatment device 14, the cooling unit 15 and/or the treatment unit 16. In one example, the power supply 20 provides a direct current voltage to a thermoelectric element of the cooling unit 15 to adjust the heat flux over a relatively large area. The processing unit 24 may monitor process parameters via sensors (not shown) placed proximate to the treatment device 14 through power line 26 to, among other things, adjust the heat removal rate based on the process parameters. The processing unit 24 may further monitor process parameters to adjust the cooling unit 15 or other components based on the process parameters.
The processing unit 24 may be in direct electrical communication with treatment device 14 through the electrical line 22 as shown in
The system 10 can also include an input device 28 and an output device 30 operatively coupled to the processing unit 24. The input device 28 may be a keyboard (shown in
Without being bound by theory, it is believed that effective conductive cooling from the treatment device 14 depends on a number of factors. Examples of factors that impact heat removal or extraction from the skin and related tissue include, for example, the surface area of the treatment unit, the temperature of the interface member, the mechanical energy delivered to the tissue, the distribution of cryoprotectant and the extent of non-uniformities in the contact between the interface member and the skin. More specifically, upon receiving input to start a treatment protocol, the processing unit 24 can cause the treatment device 14 to cycle through each segment of a prescribed treatment plan. In so doing, the treatment device 14 applies power to one or more cooling segments, such as thermoelectric coolers (e.g., TEC “zones”), to begin a cooling cycle and, for example, activate features or modes such as vibration, massage, vacuum, etc. Using temperature or heat flux sensors, the processing unit 24 determines whether the temperature and/or heat flux at one or more areas of the actuator are sufficiently close to a target temperature or target heat flux. It will be appreciated that while a region of the body (e.g., adipose tissue) has been cooled or heated to the target temperature or by a target heat flux, in actuality that region of the body may be close but not equal to the target temperature, e.g., because of the body's natural heating and cooling variations. Thus, although the system may attempt to heat or cool to the target temperature or by a target heat flux, a sensor may measure a sufficiently close temperature. If the target temperature has not been reached, power can be increased or decreased to change heat flux, as needed, to maintain the target temperature or “set-point.” When the prescribed segment duration expires, the processing unit 24 may apply the temperature and duration indicated in the next treatment profile segment. In some embodiments, temperature can be controlled using a variable other than, or in addition to, power.
A cryoprotectant is used with the treatment device 14. Among other advantages, a cryoprotectant can assist in preventing freezing of non lipid-rich tissue (e.g., dermal tissue) during treatment. Suitable cryoprotectants and processes for implementing cryoprotectants are described in commonly-assigned U.S. Patent Publication No. 2007/0255362 and U.S. patent application Ser. No. 13/011,640 filed on Jan. 21, 2011, which are hereby incorporated by reference. As used herein, “cryoprotectant” means a flowable compound that prolongs the time to freeze non lipid-rich tissue (e.g., dermal tissue) compared to an absence of the compound.
In one example of operating the system 10, the treatment device 14 is drawn against the skin of the subject 11 to achieve efficient treatment. The subject 11 generally has a body temperature of about 37° C., which is maintained at a relatively constant level by circulation of blood. As a result, blood flow through the skin and subcutaneous layer of the region to be treated acts as a heat source that counteracts the cooling of the subdermal fat. Cooling the tissue of interest accordingly requires not only removing the heat from the target tissue but also from the blood circulating through this tissue. The efficiency of cooling the tissue can be enhanced by temporarily reducing or eliminating blood flow through the treatment region using a vacuum or other technique. Applying a vacuum may also pull skin and underlying adipose tissue away from the body which can assist in cooling underlying tissue by increasing the distance between the subcutaneous fat and the relatively well-perfused muscle tissue and by allowing the underlying adipose tissue simultaneously to be cooled from two sides.
By cooling the subcutaneous tissue to a temperature lower than 37° C., subcutaneous lipid-rich cells may be damaged selectively. In general, the epidermis and dermis of the subject 11 have lower amounts of fatty acids compared to the underlying lipid-rich cells forming the subcutaneous tissues. Because non-lipid-rich cells usually can withstand colder temperatures better than lipid-rich cells, the subcutaneous lipid-rich cells can be injured selectively while maintaining the non-lipid-rich cells in the dermis and epidermis. The presence of a cryoprotectant at and/or on the dermal tissue enhances the selectivity such that the dermal tissue can withstand even colder temperatures which induce cell death in more lipid-rich tissue. For example, the temperature range may be from about −10° C. to about 0° C.
Several embodiments of the system 10 may damage, injure, disrupt or otherwise reduce subcutaneous lipid-rich cells generally without collateral damage to non-lipid-rich cells in the treatment target area. In general, it is believed that lipid-rich cells can be affected selectively (e.g., damaged, injured or disrupted) by exposing such cells to low temperatures that do not adversely affect non-lipid-rich cells to the same extent or in the same manner. As a result, lipid-rich cells, such as subcutaneous adipose tissue, can be damaged while other cells in the same region are generally not damaged even though the non-lipid-rich cells at the surface are subject to even lower temperatures. The mechanical energy provided by the applicator may further enhance the effect on lipid-rich cells by mechanically disrupting the affected lipid-rich cells.
The interface assembly 120 further controls the heat flux through a plurality of smaller zones and delivers a cryoprotectant to the target area. In one embodiment, the interface assembly 120 includes a cryoprotectant container 130 having a cavity 132 that contains a cryoprotectant 140 and an interface element 150 through which the cryoprotectant 140 can flow. The cryoprotectant container 130 can be a rigid or flexible vessel having a back panel 134 facing the cooling unit 110 and a sidewall 136 projecting from the back panel 134. The interface element 150 can be attached to the sidewall 136 to enclose the cavity 132. The interface element 150 can include a contact member 152 having a backside 153a in contact with the cryoprotectant 140 and a front side 153b configured to contact the epidermis of the subject. The contact member 152 can be a flexible barrier (e.g., membrane) such as a porous sheet of a polymeric material or a foil with small holes, a mesh, fabric or other suitable material through which the cryoprotectant 140 can flow from the backside 153a to the front side 153b. In other embodiments, the contact member 152 can be a substantially rigid barrier that is thermally conductive and configured to allow the cryoprotectant 140 to pass from the front side 153b to the backside 153a. A rigid contact member, for example, can be a plate with holes or a panel made from a porous metal material. Suitable materials for a rigid contact member 152 include aluminum, titanium, stainless steel, or other thermally conductive materials.
The interface element 150 of the application system 100 further includes an array of heating elements 154 carried by the contact member 152. The individual heating elements 154 can be arranged in a grid or other type of pattern, and each heating element 154 is independently controlled relative to the other heating elements to provide control of the heat flux through smaller, discrete zones at the interface between the target area and the interface element 150. The heating elements 154, for example, can be micro-heaters electrically coupled to a power source via a cable 155 such that the controller can selectably address individual heating elements 154. The interface element 150 can further include a plurality of temperature sensors 156 carried by the contact member 152. The temperature sensors 156 may be arranged in an array such that one or more temperature sensors can measure the heat flux through the heat flux zones associated with one or more individual heating elements 154. The temperature sensors 156 can be electrically coupled to a control unit via a cable 157 in a manner similar to the heating elements 154.
The cable 155 (
In operation, a target site of the subject is registered relative to the grid of heating elements of the interface element 150. The target site can have a single heat flux zone, or the target site can be divided into a number of different areas in which each area is associated with a corresponding heat flux zone. In either situation, a practitioner inputs the extent of desired cooling for the heat flux zones or this information can be provided to the controller by a predetermined control algorithm. The interface element 150 is positioned at the target site of the subject. In many applications, the interface element 150 and the epidermis of the target site are coapted under pressure provided by a vacuum, belt or other mechanism that forces the skin of the subject against the interface element 150. The cryoprotectant 140 in the cryoprotectant container 130 flows through the interface element 150 and contacts the skin of the subject, and a coolant is recirculated through the coolant chamber 116 of the cooling unit 110 to globally cool the back panel 134 of the cryoprotectant container 130.
The temperature at the back panel 134 can be optionally controlled regionally using TEEs 114. The cooling provided by the cooling unit 110 reduces the temperature of the cryoprotectant 140 in the cryoprotectant container 130 to a base temperature. While the interface element 150 contacts the target site, a controller selectively activates the heating elements 154 to control the heat flux through the heat flux zones across the target site. The temperature and/or heat flux at the individual heat flux zones across the target site can be monitored via the temperature sensors 156 to provide closed loop control of the heat flux according to the predetermined algorithm. Suitable algorithms for defining and controlling the heat flux are disclosed in U.S. Patent Publication No. 2010/0152824 (U.S. patent application Ser. No. 12/337,544), which is herby incorporated by reference.
Several embodiments of the application assembly 100 enhance the control of the heat flux across different regions of the target area. This can be useful because different subjects may have different deposits of lipid-rich tissue within a target area, or the subject may have particularly sensitive dermal tissue at particular regions of the target area. Moreover, the enhanced control of the heat flux through the individual heat flux zones enables more accurate control of the cooling profile within the lipid-rich tissue.
The embodiment of the interface element 400 shown in
The markers 510 can be conductive members or dielectric templates. In one example, the markers 510 are a conductive ink or magnetic ink that is deposited on the skin 520 of the patient around the perimeter of the treatment area. The heating elements 154 can include sensors that detect the presence of the inks, and the controller can then selectively operate the heating elements based on the outline of the markers 510. In another example, the markers 510 are defined by a dielectric template that has an opening in the shape of the treatment area. The heating elements 154 can be operated to focus the heat flux through the opening of the template. For example, the heating elements 154 can sense the heat flux through the corresponding heat flux zones, and the controller can determine the shape of the opening based on a greater heat flux through the opening compared to areas covered by the dielectric material.
In this embodiment, the treatment device 700 also includes a first interface assembly 120a and a second interface assembly 120b within the vacuum cup 702. More specifically, the first interface assembly 120a is adjacent the first cooling unit 710a and the second interface assembly 120b is adjacent the second cooling unit 710b. The first and second interface assemblies 120a-b can further include connectors 170 in the form of tabs or other mechanisms that can be secured by clasps or clamps 171 to releasably attach the first and second interface assemblies 120a-b to the vacuum cup 702. The first and second interface assemblies 120a-b can also be connected to each other by a flexible intermediate portion 180. The intermediate portion 180 can include a vacuum port 182 aligned with the vacuum port 704 of the vacuum cup 702, or the intermediate portion 180 can have a porous through which air can flow. In operation, the rim of the vacuum cup is placed against the skin of a subject and a vacuum is drawn within the cup. The vacuum pulls the tissue of the subject into the cup 702 and coapts the target area with the interface elements 150 of the corresponding first and second interface assemblies 120a-b. One suitable vacuum cup 702 with cooling units is described in U.S. Provisional Patent Application Ser. No. 61/174,407, filed on Apr. 30, 2009, and incorporative by reference above.
From the foregoing, it will be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but that various modifications may be made without deviating from the spirit and scope of the invention. The application systems, interface assemblies and methods may be combined in further embodiments. For example, the interface element 400 shown and described with reference to
This application claims priority to U.S. Provisional Patent Application No. 61/435,944, filed Jan. 25, 2011, entitled “DEVICES, APPLICATION SYSTEMS AND METHODS WITH LOCALIZED HEAT FLUX ZONES FOR REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS,” which is incorporated herein by reference in its entirety. The following commonly-assigned U.S. Patent Applications are incorporated herein by reference in their entirety: U.S. Patent Publication No. 2008/0287839 entitled “METHOD OF ENHANCED REMOVAL OF HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS AND TREATMENT APPARATUS HAVING AN ACTUATOR”; U.S. Pat. No. 6,032,675 entitled “FREEZING METHOD FOR CONTROLLED REMOVAL OF FATTY TISSUE BY LIPOSUCTION”; U.S. Patent Publication No. 2007/0255362 entitled “CRYOPROTECTANT FOR USE WITH A TREATMENT DEVICE FOR IMPROVED COOLING OF SUBCUTANEOUS LIPID-RICH CELLS”; U.S. Pat. No. 7,854,754 entitled “COOLING DEVICE FOR REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS”; U.S. Patent Publication No. 2011/0066216 entitled “COOLING DEVICE FOR REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS”; U.S. Patent Publication No. 2008/0077201 entitled “COOLING DEVICES WITH FLEXIBLE SENSORS”; U.S. Patent Publication No. 2008/0077211 entitled “COOLING DEVICE HAVING A PLURALITY OF CONTROLLABLE COOLING ELEMENTS TO PROVIDE A PREDETERMINED COOLING PROFILE”; U.S. Patent Publication No. 2009/0118722, filed Oct. 31, 2007, entitled “METHOD AND APPARATUS FOR COOLING SUBCUTANEOUS LIPID-RICH CELLS OR TISSUE”; U.S. Patent Publication No. 2009/0018624 entitled “LIMITING USE OF DISPOSABLE SUBJECT 11 PROTECTION DEVICES”; U.S. Patent Publication No. 2009/0018623 entitled “SYSTEM FOR TREATING LIPID-RICH REGIONS”; U.S. Patent Publication No. 2009/0018625 entitled “MANAGING SYSTEM TEMPERATURE TO REMOVE HEAT FROM LIPID-RICH REGIONS”; U.S. Patent Publication No. 2009/0018627 entitled “SECURE SYSTEM FOR REMOVING HEAT FROM LIPID-RICH REGIONS”; U.S. Patent Publication No. 2009/0018626 entitled “USER INTERFACES FOR A SYSTEM THAT REMOVES HEAT FROM LIPID-RICH REGIONS”; U.S. Pat. No. 6,041,787 entitled “USE OF CRYOPROTECTIVE AGENT COMPOUNDS DURING CRYOSURGERY”; U.S. Patent Publication No. 2009/0149929 entitled “MONITORING THE COOLING OF SUBCUTANEOUS LIPID-RICH CELLS, SUCH AS THE COOLING OF ADIPOSE TISSUE”; U.S. Provisional Patent Application Ser. No. 60/941,567 entitled “METHODS, APPARATUSES AND SYSTEMS FOR COOLING THE SKIN AND SUBCUTANEOUS TISSUE”; U.S. Patent Publication No. 2010/0081971 entitled “TREATMENT PLANNING SYSTEMS AND METHODS FOR BODY CONTOURING APPLICATIONS”; U.S. patent application Ser. No. 12/275,002 entitled “APPARATUS WITH HYDROPHILIC RESERVOIRS FOR COOLING SUBCUTANEOUS LIPID-RICH CELLS”; U.S. patent application Ser. No. 12/275,014 entitled “APPARATUS WITH HYDROPHOBIC FILTERS FOR REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS”; U.S. Patent Publication No. 2010/0152824 entitled “SYSTEMS AND METHODS WITH INTERRUPT/RESUME CAPABILITIES FOR COOLING SUBCUTANEOUS LIPID-RICH CELLS”; U.S. Patent Publication No. 2008/0077202 entitled “TISSUE TREATMENT METHODS”; U.S. Patent Publication No. 2010/0280582 entitled “DEVICE, SYSTEM AND METHOD FOR REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS”; U.S. patent application Ser. No. 12/840,235 entitled “COMBINED MODALITY TREATMENT SYSTEMS, METHODS AND APPARATUS FOR BODY CONTOURING APPLICATIONS”; U.S. Publication No. 2011/0238050 entitled “HOME-USE APPLICATORS FOR NON-INVASIVELY REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS VIA PHASE CHANGE COOLANTS, AND ASSOCIATED DEVICES, SYSTEMS AND METHODS”; and U.S. Publication No. 2011/0238051 entitled “HOME-USE APPLICATORS FOR NON-INVASIVELY REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS VIA PHASE CHANGE COOLANTS, AND ASSOCIATED DEVICES, SYSTEMS AND METHODS”.
Number | Name | Date | Kind |
---|---|---|---|
681806 | Mignault | Sep 1901 | A |
889810 | Robinson | Jun 1908 | A |
2516491 | Swastek | Jul 1950 | A |
2521780 | Dodd et al. | Sep 1950 | A |
3093135 | Hirschhorn | Jun 1963 | A |
3132688 | Nowak | May 1964 | A |
3133539 | William et al. | May 1964 | A |
3282267 | Wiliam | Nov 1966 | A |
3502080 | Hirschhorn | Mar 1970 | A |
3587577 | Smirnov et al. | Jun 1971 | A |
3591645 | Selwitz | Jul 1971 | A |
3703897 | Mack et al. | Nov 1972 | A |
3710784 | Taylor | Jan 1973 | A |
3786814 | Armao | Jan 1974 | A |
3827436 | Stumpf et al. | Aug 1974 | A |
3942519 | Shock | Mar 1976 | A |
3948269 | Zimmer | Apr 1976 | A |
3986385 | Johnston et al. | Oct 1976 | A |
4002221 | Buchalter | Jan 1977 | A |
4026299 | Sauder | May 1977 | A |
4140130 | Storm, III | Feb 1979 | A |
4178429 | Scheffer | Dec 1979 | A |
4202336 | van Gerven et al. | May 1980 | A |
4266043 | Fujii et al. | May 1981 | A |
4381009 | Del Bon et al. | Apr 1983 | A |
4396011 | Mack et al. | Aug 1983 | A |
4483341 | Witteles | Nov 1984 | A |
4528979 | Marchenko et al. | Jul 1985 | A |
4531524 | Mioduski | Jul 1985 | A |
4548212 | Leung | Oct 1985 | A |
4555313 | Duchane et al. | Nov 1985 | A |
4585002 | Kissin | Apr 1986 | A |
4603076 | Bowditch et al. | Jul 1986 | A |
4614191 | Perler | Sep 1986 | A |
4644955 | Mioduski | Feb 1987 | A |
4664110 | Schanzlin | May 1987 | A |
4700701 | Montaldi | Oct 1987 | A |
4718429 | Smidt et al. | Jan 1988 | A |
4741338 | Miyamae et al. | May 1988 | A |
4764463 | Mason et al. | Aug 1988 | A |
4802475 | Weshahy et al. | Feb 1989 | A |
4832022 | Tjulkov et al. | May 1989 | A |
4846176 | Golden | Jul 1989 | A |
4850340 | Onishi | Jul 1989 | A |
4869250 | Bitterly | Sep 1989 | A |
4880564 | Abel et al. | Nov 1989 | A |
4905697 | Heggs et al. | Mar 1990 | A |
4906463 | Cleary et al. | Mar 1990 | A |
4930317 | Klein | Jun 1990 | A |
4935345 | Guibeau et al. | Jun 1990 | A |
4961422 | Marchosky et al. | Oct 1990 | A |
4962761 | Golden | Oct 1990 | A |
4990144 | Blott | Feb 1991 | A |
5007433 | Hermsdorffer et al. | Apr 1991 | A |
5018521 | Campbell | May 1991 | A |
5024650 | Hagiwara et al. | Jun 1991 | A |
5065752 | Sessions et al. | Nov 1991 | A |
5069208 | Noppel et al. | Dec 1991 | A |
5084671 | Miyata et al. | Jan 1992 | A |
5108390 | Potocky et al. | Apr 1992 | A |
5119674 | Nielsen et al. | Jun 1992 | A |
5139496 | Hed et al. | Aug 1992 | A |
5143063 | Fellner | Sep 1992 | A |
5148804 | Hill et al. | Sep 1992 | A |
5158070 | Dory | Oct 1992 | A |
5169384 | Bosniak et al. | Dec 1992 | A |
5197466 | Marchosky et al. | Mar 1993 | A |
5207674 | Hamilton | May 1993 | A |
5221726 | Dabi et al. | Jun 1993 | A |
5264234 | Windhab et al. | Nov 1993 | A |
5277030 | Miller | Jan 1994 | A |
5314423 | Seney | May 1994 | A |
5327886 | Chiu | Jul 1994 | A |
5330745 | McDow | Jul 1994 | A |
5334131 | Omandam et al. | Aug 1994 | A |
5336616 | Livesey et al. | Aug 1994 | A |
5339541 | Owens | Aug 1994 | A |
5342617 | Gold | Aug 1994 | A |
5351677 | Kami et al. | Oct 1994 | A |
5358467 | Milstein et al. | Oct 1994 | A |
5362966 | Rosenthal et al. | Nov 1994 | A |
5372608 | Johnson | Dec 1994 | A |
5386837 | Sterzer | Feb 1995 | A |
5411541 | Bell et al. | May 1995 | A |
5427772 | Hagan | Jun 1995 | A |
5433717 | Rubinsky et al. | Jul 1995 | A |
5456703 | Beeuwkes, III | Oct 1995 | A |
5472416 | Blugerman et al. | Dec 1995 | A |
5486207 | Mahawili | Jan 1996 | A |
5497596 | Zatkulak | Mar 1996 | A |
5505726 | Meserol | Apr 1996 | A |
5505730 | Edwards | Apr 1996 | A |
5507790 | Weiss et al. | Apr 1996 | A |
5514105 | Goodman, Jr. et al. | May 1996 | A |
5514170 | Mauch | May 1996 | A |
5516505 | McDow | May 1996 | A |
5531742 | Barken | Jul 1996 | A |
5562604 | Yablon et al. | Oct 1996 | A |
5571801 | Segall et al. | Nov 1996 | A |
5575812 | Owens et al. | Nov 1996 | A |
5603221 | Maytal et al. | Feb 1997 | A |
5628769 | Saringer et al. | May 1997 | A |
5634890 | Morris | Jun 1997 | A |
5634940 | Panyard | Jun 1997 | A |
5647051 | Neer | Jul 1997 | A |
5647868 | Chinn | Jul 1997 | A |
5650450 | Lovette et al. | Jul 1997 | A |
5651773 | Perry et al. | Jul 1997 | A |
5654279 | Rubinsky et al. | Aug 1997 | A |
5654546 | Lindsay | Aug 1997 | A |
5660836 | Knowlton | Aug 1997 | A |
5665053 | Jacobs | Sep 1997 | A |
5672172 | Zupkas | Sep 1997 | A |
5700284 | Owens et al. | Dec 1997 | A |
5725483 | Podolsky | Mar 1998 | A |
5733280 | Avitall | Mar 1998 | A |
5741248 | Stern et al. | Apr 1998 | A |
5746736 | Tankovich | May 1998 | A |
5755663 | Larsen et al. | May 1998 | A |
5755753 | Knowlton | May 1998 | A |
5755755 | Panyard | May 1998 | A |
5759182 | Varney et al. | Jun 1998 | A |
5759764 | Polovina | Jun 1998 | A |
5769879 | Richards et al. | Jun 1998 | A |
5785955 | Fischer | Jul 1998 | A |
5792080 | Ookawa et al. | Aug 1998 | A |
5814040 | Nelson et al. | Sep 1998 | A |
5817050 | Klein | Oct 1998 | A |
5817149 | Owens et al. | Oct 1998 | A |
5817150 | Owens et al. | Oct 1998 | A |
5830208 | Muller | Nov 1998 | A |
5833685 | Tortal et al. | Nov 1998 | A |
5844013 | Kenndoff et al. | Dec 1998 | A |
5871524 | Knowlton | Feb 1999 | A |
5871526 | Gibbs et al. | Feb 1999 | A |
5885211 | Eppstein et al. | Mar 1999 | A |
5895418 | Saringer et al. | Apr 1999 | A |
5901707 | Goncalves et al. | May 1999 | A |
5902256 | Benaron | May 1999 | A |
5919219 | Knowlton | Jul 1999 | A |
5944748 | Mager et al. | Aug 1999 | A |
5948011 | Knowlton | Sep 1999 | A |
5954680 | Augustine et al. | Sep 1999 | A |
5964092 | Tozuka et al. | Oct 1999 | A |
5964749 | Eckhouse et al. | Oct 1999 | A |
5967976 | Larsen et al. | Oct 1999 | A |
5986167 | Arteman et al. | Nov 1999 | A |
5989286 | Owens et al. | Nov 1999 | A |
5997530 | Nelson et al. | Dec 1999 | A |
6017337 | Pira et al. | Jan 2000 | A |
6023932 | Johnston et al. | Feb 2000 | A |
6032675 | Rubinsky | Mar 2000 | A |
6039694 | Larson et al. | Mar 2000 | A |
6041787 | Rubinsky | Mar 2000 | A |
6049927 | Thomas et al. | Apr 2000 | A |
6051159 | Hao et al. | Apr 2000 | A |
6074415 | Der Ovanesian | Jun 2000 | A |
6093230 | Johnson, III et al. | Jul 2000 | A |
6102885 | Bass | Aug 2000 | A |
6104952 | Tu et al. | Aug 2000 | A |
6104959 | Spertell et al. | Aug 2000 | A |
6106517 | Zupkas | Aug 2000 | A |
6113558 | Rosenschein et al. | Sep 2000 | A |
6113559 | Klopotek | Sep 2000 | A |
6113626 | Clifton et al. | Sep 2000 | A |
6120519 | Weber et al. | Sep 2000 | A |
6151735 | Koby et al. | Nov 2000 | A |
6152952 | Owens et al. | Nov 2000 | A |
6171301 | Nelson et al. | Jan 2001 | B1 |
6226996 | Weber et al. | May 2001 | B1 |
6241753 | Knowlton | Jun 2001 | B1 |
6264649 | Whitcroft et al. | Jul 2001 | B1 |
6273884 | Altshuler et al. | Aug 2001 | B1 |
6290988 | Van Vilsteren et al. | Sep 2001 | B1 |
6311090 | Knowlton | Oct 2001 | B1 |
6311497 | Chung et al. | Nov 2001 | B1 |
6312453 | Stefanile et al. | Nov 2001 | B1 |
6350276 | Knowlton | Feb 2002 | B1 |
6354297 | Eiseman | Mar 2002 | B1 |
6357907 | Cleveland et al. | Mar 2002 | B1 |
6375673 | Clifton et al. | Apr 2002 | B1 |
6377854 | Knowlton | Apr 2002 | B1 |
6377855 | Knowlton | Apr 2002 | B1 |
6381497 | Knowlton | Apr 2002 | B1 |
6381498 | Knowlton | Apr 2002 | B1 |
6387380 | Knowlton | May 2002 | B1 |
6401722 | Krad | Jun 2002 | B1 |
6405090 | Knowlton | Jun 2002 | B1 |
6413255 | Stern | Jul 2002 | B1 |
6425912 | Knowlton | Jul 2002 | B1 |
6426445 | Young et al. | Jul 2002 | B1 |
6430446 | Knowlton | Aug 2002 | B1 |
6430956 | Haas et al. | Aug 2002 | B1 |
6438424 | Knowlton | Aug 2002 | B1 |
6438964 | Giblin | Aug 2002 | B1 |
6453202 | Knowlton | Sep 2002 | B1 |
6458888 | Hood et al. | Oct 2002 | B1 |
6461378 | Knowlton | Oct 2002 | B1 |
6470216 | Knowlton | Oct 2002 | B1 |
6471693 | Carroll et al. | Oct 2002 | B1 |
6475211 | Chess et al. | Nov 2002 | B2 |
6494844 | Van Bladel et al. | Dec 2002 | B1 |
6497721 | Ginsburg et al. | Dec 2002 | B2 |
6508831 | Kushnir | Jan 2003 | B1 |
6514244 | Pope et al. | Feb 2003 | B2 |
6519964 | Bieberich | Feb 2003 | B2 |
6523354 | Tolbert | Feb 2003 | B1 |
6527765 | Kelman et al. | Mar 2003 | B2 |
6527798 | Ginsburg et al. | Mar 2003 | B2 |
6544248 | Bass | Apr 2003 | B1 |
6548297 | Kuri-Harcuch et al. | Apr 2003 | B1 |
6551348 | Blalock et al. | Apr 2003 | B1 |
6551349 | Lasheras et al. | Apr 2003 | B2 |
6569189 | Augustine et al. | May 2003 | B1 |
6585652 | Lang et al. | Jul 2003 | B2 |
6592577 | Abboud et al. | Jul 2003 | B2 |
6605080 | Altshuler et al. | Aug 2003 | B1 |
6620188 | Ginsburg et al. | Sep 2003 | B1 |
6620189 | Machold et al. | Sep 2003 | B1 |
6623430 | Slayton et al. | Sep 2003 | B1 |
6626854 | Friedman et al. | Sep 2003 | B2 |
6632219 | Baranov et al. | Oct 2003 | B1 |
6635053 | Lalonde et al. | Oct 2003 | B1 |
6645162 | Friedman et al. | Nov 2003 | B2 |
6645229 | Matsumura et al. | Nov 2003 | B2 |
6648904 | Altshuler et al. | Nov 2003 | B2 |
6656208 | Grahn et al. | Dec 2003 | B2 |
6662054 | Kreindel et al. | Dec 2003 | B2 |
6682550 | Clifton et al. | Jan 2004 | B2 |
6685731 | Kushnir et al. | Feb 2004 | B2 |
6695874 | Machold et al. | Feb 2004 | B2 |
6699266 | Lachenbruch et al. | Mar 2004 | B2 |
6718785 | Bieberich | Apr 2004 | B2 |
6741895 | Gafni et al. | May 2004 | B1 |
6743222 | Durkin et al. | Jun 2004 | B2 |
6746474 | Saadat | Jun 2004 | B2 |
6749624 | Knowlton | Jun 2004 | B2 |
6764493 | Weber et al. | Jul 2004 | B1 |
6764502 | Bieberich | Jul 2004 | B2 |
6789545 | Littrup et al. | Sep 2004 | B2 |
6820961 | Johnson | Nov 2004 | B2 |
6821274 | McHale et al. | Nov 2004 | B2 |
6840955 | Ein | Jan 2005 | B2 |
6849075 | Bertolero et al. | Feb 2005 | B2 |
6878144 | Altshuler et al. | Apr 2005 | B2 |
6889090 | Kreindel | May 2005 | B2 |
6904956 | Noel | Jun 2005 | B2 |
6918903 | Bass | Jul 2005 | B2 |
6927316 | Faries, Jr. et al. | Aug 2005 | B1 |
6942022 | Blangetti et al. | Sep 2005 | B2 |
6945942 | Van Bladel et al. | Sep 2005 | B2 |
6948903 | Ablabutyan et al. | Sep 2005 | B2 |
7005558 | Johansson et al. | Feb 2006 | B1 |
7022121 | Stern et al. | Apr 2006 | B2 |
7037326 | Lee et al. | May 2006 | B2 |
7060061 | Altshuler et al. | Jun 2006 | B2 |
7077858 | Fletcher et al. | Jul 2006 | B2 |
7081111 | Svaasand et al. | Jul 2006 | B2 |
7096204 | Chen et al. | Aug 2006 | B1 |
7112712 | Ancell | Sep 2006 | B1 |
7115123 | Knowlton et al. | Oct 2006 | B2 |
7183360 | Daniel et al. | Feb 2007 | B2 |
7189252 | Krueger | Mar 2007 | B2 |
7192426 | Baust et al. | Mar 2007 | B2 |
7204832 | Altshuler et al. | Apr 2007 | B2 |
7220778 | Anderson et al. | May 2007 | B2 |
7258674 | Cribbs et al. | Aug 2007 | B2 |
7276058 | Altshuler et al. | Oct 2007 | B2 |
7367341 | Anderson et al. | May 2008 | B2 |
7572268 | Babaev | Aug 2009 | B2 |
7604632 | Howlett et al. | Oct 2009 | B2 |
7613523 | Eggers et al. | Nov 2009 | B2 |
7615016 | Barthe et al. | Nov 2009 | B2 |
7713266 | Elkins et al. | May 2010 | B2 |
7780656 | Tankovich | Aug 2010 | B2 |
7799018 | Goulko | Sep 2010 | B2 |
7824437 | Saunders | Nov 2010 | B1 |
7850683 | Elkins et al. | Dec 2010 | B2 |
7854754 | Ting et al. | Dec 2010 | B2 |
7862558 | Elkins et al. | Jan 2011 | B2 |
7959657 | Harsy et al. | Jun 2011 | B1 |
7963959 | Da Silva et al. | Jun 2011 | B2 |
7993330 | Goulko | Aug 2011 | B2 |
7998137 | Elkins et al. | Aug 2011 | B2 |
8133180 | Slayton et al. | Mar 2012 | B2 |
8246611 | Paithankar et al. | Aug 2012 | B2 |
8333700 | Barthe et al. | Dec 2012 | B1 |
8366622 | Slayton et al. | Feb 2013 | B2 |
8372130 | Young et al. | Feb 2013 | B2 |
8397518 | Vistakula et al. | Mar 2013 | B1 |
8414631 | Quisenberry et al. | Apr 2013 | B2 |
8433400 | Prushinskaya et al. | Apr 2013 | B2 |
8506486 | Slayton et al. | Aug 2013 | B2 |
8523775 | Barthe et al. | Sep 2013 | B2 |
8523791 | Castel | Sep 2013 | B2 |
8523927 | Levinson et al. | Sep 2013 | B2 |
8535228 | Slayton et al. | Sep 2013 | B2 |
8603073 | Allison | Dec 2013 | B2 |
8636665 | Slayton et al. | Jan 2014 | B2 |
8641622 | Barthe et al. | Feb 2014 | B2 |
8663112 | Slayton et al. | Mar 2014 | B2 |
8672848 | Slayton et al. | Mar 2014 | B2 |
8676332 | Fahey | Mar 2014 | B2 |
8690778 | Slayton et al. | Apr 2014 | B2 |
8690779 | Slayton et al. | Apr 2014 | B2 |
8690780 | Slayton et al. | Apr 2014 | B2 |
8702774 | Baker et al. | Apr 2014 | B2 |
8758215 | Legendre et al. | Jun 2014 | B2 |
8764693 | Graham et al. | Jul 2014 | B1 |
8834547 | Anderson et al. | Sep 2014 | B2 |
20010005791 | Ginsburg et al. | Jun 2001 | A1 |
20010007952 | Shimizu | Jul 2001 | A1 |
20010023364 | Ahn | Sep 2001 | A1 |
20010031459 | Fahy et al. | Oct 2001 | A1 |
20010039439 | Elkins et al. | Nov 2001 | A1 |
20010045104 | Bailey et al. | Nov 2001 | A1 |
20010047196 | Ginsburg et al. | Nov 2001 | A1 |
20020026226 | Ein | Feb 2002 | A1 |
20020032473 | Kushnir et al. | Mar 2002 | A1 |
20020042607 | Palmer et al. | Apr 2002 | A1 |
20020049483 | Knowlton | Apr 2002 | A1 |
20020058975 | Bieberich | May 2002 | A1 |
20020062142 | Knowlton | May 2002 | A1 |
20020082668 | Ingman | Jun 2002 | A1 |
20020103520 | Latham | Aug 2002 | A1 |
20020107558 | Clifton et al. | Aug 2002 | A1 |
20020117293 | Campbell | Aug 2002 | A1 |
20020151830 | Kahn | Oct 2002 | A1 |
20020151887 | Stern et al. | Oct 2002 | A1 |
20020156509 | Cheung | Oct 2002 | A1 |
20020188286 | Quijano et al. | Dec 2002 | A1 |
20030032900 | Ella | Feb 2003 | A1 |
20030044764 | Soane et al. | Mar 2003 | A1 |
20030055414 | Altshuler et al. | Mar 2003 | A1 |
20030062040 | Lurie et al. | Apr 2003 | A1 |
20030069618 | Smith et al. | Apr 2003 | A1 |
20030077329 | Kipp et al. | Apr 2003 | A1 |
20030079488 | Bieberich | May 2003 | A1 |
20030100936 | Altshuler et al. | May 2003 | A1 |
20030109908 | Lachenbruch et al. | Jun 2003 | A1 |
20030109910 | Lachenbruch et al. | Jun 2003 | A1 |
20030109911 | Lachenbruch et al. | Jun 2003 | A1 |
20030114885 | Nova et al. | Jun 2003 | A1 |
20030120268 | Bertolero et al. | Jun 2003 | A1 |
20030125649 | McIntosh et al. | Jul 2003 | A1 |
20030187488 | Kreindel et al. | Oct 2003 | A1 |
20030199226 | Sommer et al. | Oct 2003 | A1 |
20030199859 | Altshuler et al. | Oct 2003 | A1 |
20030220594 | Halvorson et al. | Nov 2003 | A1 |
20030220674 | Anderson et al. | Nov 2003 | A1 |
20030236487 | Knowlton | Dec 2003 | A1 |
20040006328 | Anderson | Jan 2004 | A1 |
20040009936 | Tang et al. | Jan 2004 | A1 |
20040024437 | Machold et al. | Feb 2004 | A1 |
20040030332 | Knowlton et al. | Feb 2004 | A1 |
20040034341 | Altshuler et al. | Feb 2004 | A1 |
20040039312 | Hillstead et al. | Feb 2004 | A1 |
20040044384 | Leber et al. | Mar 2004 | A1 |
20040049178 | Abboud et al. | Mar 2004 | A1 |
20040073079 | Altshuler et al. | Apr 2004 | A1 |
20040074629 | Noel | Apr 2004 | A1 |
20040077977 | Ella et al. | Apr 2004 | A1 |
20040082886 | Timpson | Apr 2004 | A1 |
20040093042 | Altshuler et al. | May 2004 | A1 |
20040104012 | Zhou et al. | Jun 2004 | A1 |
20040106867 | Eshel et al. | Jun 2004 | A1 |
20040133251 | Altshuler et al. | Jul 2004 | A1 |
20040162596 | Altshuler et al. | Aug 2004 | A1 |
20040199226 | Shadduck | Oct 2004 | A1 |
20040210214 | Knowlton | Oct 2004 | A1 |
20040210287 | Greene | Oct 2004 | A1 |
20040249427 | Nabilsi et al. | Dec 2004 | A1 |
20040259855 | Anderson et al. | Dec 2004 | A1 |
20040260209 | Ella et al. | Dec 2004 | A1 |
20040260210 | Ella et al. | Dec 2004 | A1 |
20040260211 | Maalouf | Dec 2004 | A1 |
20050010197 | Lau et al. | Jan 2005 | A1 |
20050049526 | Baer | Mar 2005 | A1 |
20050049543 | Anderson et al. | Mar 2005 | A1 |
20050049661 | Koffroth | Mar 2005 | A1 |
20050113725 | Masuda | May 2005 | A1 |
20050145372 | Noel | Jul 2005 | A1 |
20050154431 | Quistgaard et al. | Jul 2005 | A1 |
20050159986 | Breeland et al. | Jul 2005 | A1 |
20050177075 | Meunier et al. | Aug 2005 | A1 |
20050182462 | Chornenky et al. | Aug 2005 | A1 |
20050187597 | Vanderschuit | Aug 2005 | A1 |
20050203446 | Takashima | Sep 2005 | A1 |
20050215987 | Slatkine | Sep 2005 | A1 |
20050222565 | Manstein | Oct 2005 | A1 |
20050251117 | Anderson et al. | Nov 2005 | A1 |
20050251120 | Anderson et al. | Nov 2005 | A1 |
20050277859 | Carlsmith et al. | Dec 2005 | A1 |
20050283144 | Shiono et al. | Dec 2005 | A1 |
20060030778 | Mendlein et al. | Feb 2006 | A1 |
20060036300 | Kreindel | Feb 2006 | A1 |
20060074313 | Slayton et al. | Apr 2006 | A1 |
20060079852 | Bubb et al. | Apr 2006 | A1 |
20060122509 | Desilets | Jun 2006 | A1 |
20060189964 | Anderson et al. | Aug 2006 | A1 |
20060195168 | Dunbar et al. | Aug 2006 | A1 |
20060200063 | Munro et al. | Sep 2006 | A1 |
20060206040 | Greenberg et al. | Sep 2006 | A1 |
20060234899 | Nekmard et al. | Oct 2006 | A1 |
20060259102 | Slatkine | Nov 2006 | A1 |
20060270745 | Hunt et al. | Nov 2006 | A1 |
20060293734 | Scott et al. | Dec 2006 | A1 |
20070010861 | Anderson et al. | Jan 2007 | A1 |
20070032561 | Lin et al. | Feb 2007 | A1 |
20070038156 | Rosenberg | Feb 2007 | A1 |
20070073367 | Jones et al. | Mar 2007 | A1 |
20070088413 | Weber | Apr 2007 | A1 |
20070129714 | Elkins et al. | Jun 2007 | A1 |
20070135876 | Weber | Jun 2007 | A1 |
20070141265 | Thomson | Jun 2007 | A1 |
20070179482 | Anderson et al. | Aug 2007 | A1 |
20070198071 | Ting et al. | Aug 2007 | A1 |
20070239075 | Rosenberg et al. | Oct 2007 | A1 |
20070249519 | Guha et al. | Oct 2007 | A1 |
20070255187 | Branch | Nov 2007 | A1 |
20070255362 | Levinson | Nov 2007 | A1 |
20070265585 | Joshi et al. | Nov 2007 | A1 |
20070270925 | Levinson | Nov 2007 | A1 |
20070282249 | Quisenberry et al. | Dec 2007 | A1 |
20080046047 | Jacobs | Feb 2008 | A1 |
20080058784 | Manstein et al. | Mar 2008 | A1 |
20080077201 | Levinson et al. | Mar 2008 | A1 |
20080077202 | Levinson | Mar 2008 | A1 |
20080077211 | Levinson et al. | Mar 2008 | A1 |
20080097207 | Cai et al. | Apr 2008 | A1 |
20080139901 | Altshuler et al. | Jun 2008 | A1 |
20080140061 | Toubia et al. | Jun 2008 | A1 |
20080140371 | Warner | Jun 2008 | A1 |
20080161892 | Mercuro et al. | Jul 2008 | A1 |
20080183164 | Elkins et al. | Jul 2008 | A1 |
20080188915 | Mills | Aug 2008 | A1 |
20080269851 | Deem et al. | Oct 2008 | A1 |
20080287839 | Rosen et al. | Nov 2008 | A1 |
20090012434 | Anderson | Jan 2009 | A1 |
20090018623 | Levinson et al. | Jan 2009 | A1 |
20090018624 | Levinson et al. | Jan 2009 | A1 |
20090018625 | Levinson et al. | Jan 2009 | A1 |
20090018626 | Levinson et al. | Jan 2009 | A1 |
20090018627 | Levinson et al. | Jan 2009 | A1 |
20090112134 | Avni | Apr 2009 | A1 |
20090118722 | Ebbers | May 2009 | A1 |
20090149929 | Levinson et al. | Jun 2009 | A1 |
20090149930 | Schenck | Jun 2009 | A1 |
20090171334 | Elkins et al. | Jul 2009 | A1 |
20090276018 | Brader | Nov 2009 | A1 |
20090299234 | Cho et al. | Dec 2009 | A1 |
20090312676 | Rousso et al. | Dec 2009 | A1 |
20090312693 | Thapliyal et al. | Dec 2009 | A1 |
20100015190 | Hassler | Jan 2010 | A1 |
20100030306 | Edelman et al. | Feb 2010 | A1 |
20100036295 | Altshuler et al. | Feb 2010 | A1 |
20100042087 | Goldboss et al. | Feb 2010 | A1 |
20100049178 | Deem et al. | Feb 2010 | A1 |
20100081971 | Allison | Apr 2010 | A1 |
20100087806 | Da Silva et al. | Apr 2010 | A1 |
20100152824 | Allison | Jun 2010 | A1 |
20100168726 | Brookman | Jul 2010 | A1 |
20100179531 | Nebrigic | Jul 2010 | A1 |
20100198064 | Perl et al. | Aug 2010 | A1 |
20100217349 | Fahey et al. | Aug 2010 | A1 |
20100268220 | Johnson et al. | Oct 2010 | A1 |
20100280582 | Baker et al. | Nov 2010 | A1 |
20110040235 | Castel | Feb 2011 | A1 |
20110040299 | Kim et al. | Feb 2011 | A1 |
20110046523 | Altshuler et al. | Feb 2011 | A1 |
20110060323 | Baust et al. | Mar 2011 | A1 |
20110066083 | Tosaya et al. | Mar 2011 | A1 |
20110077557 | Wing et al. | Mar 2011 | A1 |
20110077723 | Parish et al. | Mar 2011 | A1 |
20110112520 | Kreindel | May 2011 | A1 |
20110144631 | Elkins et al. | Jun 2011 | A1 |
20110152849 | Baust et al. | Jun 2011 | A1 |
20110172651 | Altshuler et al. | Jul 2011 | A1 |
20110189129 | Qiu et al. | Aug 2011 | A1 |
20110196395 | Maschke | Aug 2011 | A1 |
20110202048 | Nebrigic | Aug 2011 | A1 |
20110257642 | Griggs, III | Oct 2011 | A1 |
20110301585 | Goulko | Dec 2011 | A1 |
20110313411 | Anderson et al. | Dec 2011 | A1 |
20110313412 | Kim et al. | Dec 2011 | A1 |
20120010609 | Deem et al. | Jan 2012 | A1 |
20120022518 | Levinson | Jan 2012 | A1 |
20120022622 | Johnson et al. | Jan 2012 | A1 |
20120065629 | Elkins et al. | Mar 2012 | A1 |
20120083862 | Altshuler et al. | Apr 2012 | A1 |
20120109041 | Munz | May 2012 | A1 |
20120158100 | Schomacker | Jun 2012 | A1 |
20120209363 | Williams, III et al. | Aug 2012 | A1 |
20120233736 | Tepper et al. | Sep 2012 | A1 |
20120253416 | Erez et al. | Oct 2012 | A1 |
20120259322 | Fourkas et al. | Oct 2012 | A1 |
20120277674 | Clark, III et al. | Nov 2012 | A1 |
20120310232 | Erez | Dec 2012 | A1 |
20130018236 | Altshuler et al. | Jan 2013 | A1 |
20130019374 | Schwartz | Jan 2013 | A1 |
20130073017 | Liu et al. | Mar 2013 | A1 |
20130079684 | Rosen et al. | Mar 2013 | A1 |
20130150844 | Deem et al. | Jun 2013 | A1 |
20130166003 | Johnson et al. | Jun 2013 | A1 |
20130190744 | Avram et al. | Jul 2013 | A1 |
20130238062 | Ron Edoute et al. | Sep 2013 | A1 |
20130245507 | Khorassani Zadeh | Sep 2013 | A1 |
20130253384 | Anderson et al. | Sep 2013 | A1 |
20130253493 | Anderson et al. | Sep 2013 | A1 |
20130253494 | Anderson et al. | Sep 2013 | A1 |
20130253495 | Anderson et al. | Sep 2013 | A1 |
20130253496 | Anderson et al. | Sep 2013 | A1 |
20130331914 | Lee et al. | Dec 2013 | A1 |
20140005759 | Fahey et al. | Jan 2014 | A1 |
20140005760 | Levinson et al. | Jan 2014 | A1 |
20140067025 | Levinson et al. | Mar 2014 | A1 |
20140142469 | Britva et al. | May 2014 | A1 |
20140200487 | Ramdas et al. | Jul 2014 | A1 |
20140200488 | Seo et al. | Jul 2014 | A1 |
20140222121 | Spence et al. | Aug 2014 | A1 |
20140277219 | Nanda | Sep 2014 | A1 |
20140277302 | Weber et al. | Sep 2014 | A1 |
20140277303 | Biser et al. | Sep 2014 | A1 |
20140303697 | Anderson et al. | Oct 2014 | A1 |
20150209174 | Abreu | Jul 2015 | A1 |
20150216719 | DeBenedictis et al. | Aug 2015 | A1 |
20150216720 | DeBenedictis et al. | Aug 2015 | A1 |
20150216816 | O'Neil et al. | Aug 2015 | A1 |
20150223975 | Anderson et al. | Aug 2015 | A1 |
20150328077 | Levinson | Nov 2015 | A1 |
20150335468 | Rose et al. | Nov 2015 | A1 |
20150342780 | Levinson et al. | Dec 2015 | A1 |
20160051308 | Pennybacker et al. | Feb 2016 | A1 |
20160051401 | Yee et al. | Feb 2016 | A1 |
20160135985 | Anderson | May 2016 | A1 |
20160324684 | Levinson et al. | Nov 2016 | A1 |
20170079833 | Frangineas, Jr. et al. | Mar 2017 | A1 |
20170105869 | Frangineas, Jr. et al. | Apr 2017 | A1 |
20170165105 | Anderson et al. | Jun 2017 | A1 |
20170196731 | Debenedictis et al. | Jul 2017 | A1 |
20170239079 | Root et al. | Aug 2017 | A1 |
20170325992 | DeBenedictis et al. | Nov 2017 | A1 |
20170325993 | Jimenez Lozano et al. | Nov 2017 | A1 |
20170326042 | Zeng et al. | Nov 2017 | A1 |
20170326346 | Jimenez Lozano et al. | Nov 2017 | A1 |
Number | Date | Country |
---|---|---|
2011253768 | Jun 2012 | AU |
2441489 | Mar 2005 | CA |
333982 | Nov 1958 | CH |
86200604 | Oct 1987 | CN |
2514795 | Oct 2002 | CN |
1511503 | Jul 2004 | CN |
1741777 | Mar 2006 | CN |
1817990 | Aug 2006 | CN |
2843367 | Dec 2006 | CN |
2850584 | Dec 2006 | CN |
2850585 | Dec 2006 | CN |
200970265 | Nov 2007 | CN |
532976 | Sep 1931 | DE |
2851602 | Jun 1980 | DE |
4213584 | Nov 1992 | DE |
4224595 | Jan 1994 | DE |
4238291 | May 1994 | DE |
4445627 | Jun 1996 | DE |
19800416 | Jul 1999 | DE |
0263069 | Apr 1988 | EP |
0397043 | Nov 1990 | EP |
0406244 | Jan 1991 | EP |
0598824 | Jun 1994 | EP |
1030611 | Aug 2000 | EP |
1568395 | Aug 2005 | EP |
2260801 | Dec 2010 | EP |
2289598 | Mar 2011 | EP |
2527005 | Nov 2012 | EP |
854937 | Apr 1940 | FR |
2744358 | Aug 1997 | FR |
2767476 | Feb 1999 | FR |
2776920 | Oct 1999 | FR |
2789893 | Aug 2000 | FR |
2805989 | Sep 2001 | FR |
387960 | Feb 1933 | GB |
2120944 | Dec 1983 | GB |
2248183 | Apr 1992 | GB |
2263872 | Aug 1993 | GB |
2286660 | Aug 1995 | GB |
2323659 | Sep 1998 | GB |
63076895 | Apr 1988 | JP |
01223961 | Sep 1989 | JP |
10223961 | Sep 1989 | JP |
03051964 | Mar 1991 | JP |
3259975 | Nov 1991 | JP |
4093597 | Mar 1992 | JP |
6282977 | Oct 1994 | JP |
7194666 | Aug 1995 | JP |
7268274 | Oct 1995 | JP |
09164163 | Jun 1997 | JP |
10216169 | Aug 1998 | JP |
3065657 | Nov 1999 | JP |
2000503154 | Mar 2000 | JP |
2001046416 | Feb 2001 | JP |
2002543668 | Dec 2002 | JP |
2004013600 | Jan 2004 | JP |
2004159666 | Jun 2004 | JP |
2004073812 | Nov 2004 | JP |
2005039790 | Feb 2005 | JP |
3655820 | Mar 2005 | JP |
200565984 | Mar 2005 | JP |
2005110755 | Apr 2005 | JP |
2005520608 | Jul 2005 | JP |
2005237908 | Sep 2005 | JP |
2008323716 | Nov 2005 | JP |
2006026001 | Feb 2006 | JP |
2006130055 | May 2006 | JP |
2005520608 | Jul 2006 | JP |
2006520949 | Sep 2006 | JP |
2008532591 | Aug 2008 | JP |
2009189757 | Aug 2009 | JP |
200173222 | Dec 1999 | KR |
102004009450 | Nov 2004 | KR |
20090000258 | Jan 2009 | KR |
1020130043299 | Apr 2013 | KR |
1020140038165 | Mar 2014 | KR |
2036667 01 | Jun 1995 | RU |
532976 | Nov 1978 | SU |
0476644 | Feb 2002 | TW |
WO1985003216 | Aug 1985 | WO |
WO9705828 | Nov 1990 | WO |
9114417 | Oct 1991 | WO |
WO9404116 | Mar 1994 | WO |
9623447 | Aug 1996 | WO |
9626693 | Sep 1996 | WO |
WO-9636293 | Nov 1996 | WO |
WO-9637158 | Nov 1996 | WO |
WO9637158 | Nov 1996 | WO |
WO9636293 | Nov 1996 | WO |
9704832 | Feb 1997 | WO |
WO9705828 | Feb 1997 | WO |
WO-9705828 | Feb 1997 | WO |
WO9722262 | Jun 1997 | WO |
WO-9722262 | Jun 1997 | WO |
9724088 | Jul 1997 | WO |
9748440 | Dec 1997 | WO |
9829134 | Jul 1998 | WO |
9831321 | Jul 1998 | WO |
WO-9841157 | Sep 1998 | WO |
WO-9841156 | Sep 1998 | WO |
WO9841157 | Sep 1998 | WO |
9909928 | Mar 1999 | WO |
9916502 | Apr 1999 | WO |
WO9938469 | Aug 1999 | WO |
WO-9938469 | Aug 1999 | WO |
9949937 | Oct 1999 | WO |
WO-0044346 | Aug 2000 | WO |
WO2000067685 | Nov 2000 | WO |
0100269 | Jan 2001 | WO |
0113989 | Mar 2001 | WO |
WO0114012 | Mar 2001 | WO |
WO2001014012 | Mar 2001 | WO |
0134048 | May 2001 | WO |
WO-0205736 | Jan 2002 | WO |
WO-02102921 | Dec 2002 | WO |
WO-200307859 | Jan 2003 | WO |
WO-03078596 | Sep 2003 | WO |
03079916 | Oct 2003 | WO |
WO-04000098 | Dec 2003 | WO |
WO-04080279 | Sep 2004 | WO |
WO-05046540 | May 2005 | WO |
2005060354 | Jul 2005 | WO |
WO2005096979 | Oct 2005 | WO |
2005112815 | Dec 2005 | WO |
WO-06066226 | Jun 2006 | WO |
WO2006094348 | Sep 2006 | WO |
2006116603 | Nov 2006 | WO |
WO-06127467 | Nov 2006 | WO |
2007028975 | Mar 2007 | WO |
WO-07041642 | Apr 2007 | WO |
WO2007127924 | Nov 2007 | WO |
2007145421 | Dec 2007 | WO |
2007145422 | Dec 2007 | WO |
2008006018 | Jan 2008 | WO |
2008039556 | Apr 2008 | WO |
WO2008039557 | Apr 2008 | WO |
2008055243 | May 2008 | WO |
WO2008143678 | Nov 2008 | WO |
WO-2010077841 | Jul 2010 | WO |
WO-2010127315 | Nov 2010 | WO |
WO-2012012296 | Jan 2012 | WO |
2013013059 | Jan 2013 | WO |
2013075006 | May 2013 | WO |
2013075016 | May 2013 | WO |
2013190337 | Dec 2013 | WO |
2014151872 | Sep 2014 | WO |
2014191263 | Dec 2014 | WO |
2015117001 | Aug 2015 | WO |
2015117005 | Aug 2015 | WO |
2015117026 | Aug 2015 | WO |
2015117032 | Aug 2015 | WO |
2015117036 | Aug 2015 | WO |
2016028796 | Feb 2016 | WO |
2016048721 | Mar 2016 | WO |
Entry |
---|
European Search Report, European Patent Application No. EP07761461; Applicant: Zeltiq Aesthetics, Inc., dated Apr. 25, 2012, 9 pages. |
European Search Report, Supplement, European Patent Application No. EP08798416.7, Applicant: Zeltiq Aesthetics, Inc., dated Jan. 12, 2012, 7 pages. |
European Search Report, Supplement, European Patent Application No. EP09836823, Applicant: Zeltiq Aesthetics, Inc., dated May 15, 2012, 5 pages. |
Final Office Action; U.S. Appl. No. 11/741,271; dated Jul. 19, 2012, 8 pages. |
Final Office Action; U.S. Appl. No. 11/750,953; dated Jul. 5, 2012, 11 pages. |
International Search Report and Written Opinion for PCT/US2012/022585; dated May 18, 2012, 12 pages. |
Non-Final Office Action; U.S. Appl. No. 11/528,189; dated Apr. 6, 2012, 9 pages. |
Non-Final Office Action; U.S. Appl. No. 11/777,992; dated Jun. 22, 2012, 5 pages. |
Pre-Interview Office Action; U.S. Appl. No. 11/434,478; dated May 6, 2010, 4 pages. |
Ardevol, “Cooling rates of tissue samples during freezing with liquid nitrogen,” J. of Biochem and Biophysical Methods, 27, 77-86 (1993). |
Bohm et al., “Saline-enhanced radiofrequency ablation of breast tissue: an in vitro feasibility study,” Invest Radiol, 2000, pp. 149-57, vol. 35—issue (3). |
Bondei, E. et al., “Disorders of Subcutaneous Tissue (Cold Panniculitis),” Dermatology in General Medicine, Chapter 108, Section 16: 1333-1334, 1993. |
Burge, S.M. et al., “Hair Follicle Destruction and Regeneration in Guinea Pig Skin after Cutaneous Freeze Injury,” Cryobiology, 27(2): 153-163, 1990. |
Coban, “Ischemia-Reperfusion Injury of Adipofascial Tissue: An Experimental Study Evaluating early Histologic and Biochemical Alterations in Rats,” Mediators of Inflammation, 2005, 5, 304-308. |
Disclosure re: “Method and Apparatus for Regional Fat Reduction Using Controlled and Sustained Cooling of Skin Surface”. |
Donski et al., “The Effects of Cooling no Experimental Free Flap Survival,” Brit J Plas Surg, 1980, pp. 353-360, vol. 33. |
Duncan, W.C. et al., “Cold Panniculitis,” Arch. Derm., 94:722-24, 1966. |
Epstein, E.H. et al., “Popsicle Panniculitis,” The New England Journal of Medicine, 282(17):996-67, 1970. |
European Search Report, European Patent Application No. 10167756.5, Applicant: The General Hospital Corporation, dated Aug. 31, 2010, 6 pages. |
Final Office Action; U.S. Appl. No. 10/391,221; dated Aug. 24, 2006, 4 pages. |
Final Office Action; U.S. Appl. No. 11/016,196; dated Mar. 23, 2010, 12 pages. |
Final Office Action; U.S. Appl. No. 11/435,502; dated Mar. 29, 2010, 11 pages. |
Final Office Action; U.S. Appl. No. 11/528,225; dated Dec. 29, 2010, 12 pages. |
Final Office Action; U.S. Appl. No. 11/558,046; dated Mar. 30, 2011, 17 pages. |
Gage, “Current Progress in Cryosurgery,” Cryobiology 25, 483-486 (1988). |
Hale et al., “Influence of chronic heat exposure and prolonged food deprivation on execretion of mahnesium, phosphorus, calcium, hydrogen ion & ketones,” Aerosp Med, 1968, pp. 919-26, vol. 39—issue (9). |
Heller-Page et al., “Temperature-dependent skin disorders,” Journal of the American Academy of Dermatology, May 1988, vol. 18, No. 5, Pt 1, pp. 1003-1019. |
Hemmingsson, “Attenuation in Human muscle and Fat Tissue in Vivo and in Vitro,” Acta Radiologica Diagnosis 23, 149-151 (1982). |
Henry et al., “Les Dermatoses Hivernales,” Rev Med Liege, 1999, 54:11, 864-866. [Abstract Attached]. |
Holman, “Variation in cryolesion penetration due to probe size and tissue thermal conductivity,” Ann. Thorac. Surg. 53, 123-126 (1992). |
Hong, “Patterns of Ice Formulation in Normal and Malignant Breast Tissue,” Cryobiology 31, 109-120 (1994). |
International Search Report and Written Opinion for PCT/US2007/023492; Applicant: Zeltiq Aesthetics, Inc.; dated May 15, 2008, 7 pages. |
International Search Report and Written Opinion for PCT/US2007/064016; Applicant: Juniper Medical, Inc.; dated Jul. 20, 2007, 13 pages. |
International Search Report and Written Opinion for PCT/US2007/064017; Applicant: Juniper Medical, Inc.; dated Oct. 26, 2007, 16 pages. |
International Search Report and Written Opinion for PCT/US2007/064018; Applicant: Juniper Medical, Inc.; dated Jul. 26, 2007, 13 pages. |
International Search Report and Written Opinion for PCT/US2007/067638; Applicant: Juniper Medical, Inc.; dated Jan. 10, 2008, 11 pages. |
International Search Report and Written Opinion for PCT/US2007/069694; Applicant: Juniper Medical, Inc.; dated Nov. 23, 2007, 12 pages. |
International Search Report and Written Opinion for PCT/US2007/075935; Applicant: Zeltiq Aesthetics, Inc.; dated Apr. 10, 2008, 12 pages. |
International Search Report and Written Opinion for PCT/US2007/083255; Applicant: Zeltiq Aesthetics, Inc.; dated Aug. 11, 2008, 8 pages. |
International Search Report and Written Opinion for PCT/US2008/073930; Applicant: Zeltiq Aesthetics, Inc.; dated Nov. 7, 2008, 10 pages. |
International Search Report and Written Opinion for PCT/US2007/062508; Applicant: Juniper Medical, Inc.; dated Jul. 20, 2007, 13 pages. |
International Search Report and Written Opinion for PCT/US2009/058088; Applicant: Zeltiq Aesthetics, Inc.; dated Nov. 20, 2009, 14 pages. |
International Search Report and Written Opinion for PCT/US2009/067973; Applicant: Zeltiq Aesthetics, Inc.; dated Feb. 18, 2010, 10 pages. |
International Search Report for EP07758558.6; Applicant: Zeltiq Aesthetics, Inc.; dated Jul. 20, 2007, 4 pages. |
International Search Report and Written Opinion for PCT/US2005/045988; Applicant: The General Hospital Corporation; dated Apr. 25, 2006, 14 pages. |
International Search Report and Written Opinion for PCT/US2010/033290; Applicant: Zeltiq Aesthetics, Inc.; dated Feb. 25, 2011, 12 pages. |
International Search Report and Written Opinion for PCT/US2011/022112; Applicant: Zeltiq Aesthetics, Inc.; dated Mar. 18, 2011, 11 pages. |
International Search Report and Written Opinion for PCT/US2011/022444; Applicant: Zeltiq Aesthetics, Inc., dated Mar. 29, 2011, 14 pages. |
Kellum, R.E. et al., “Sclerema Neonatorum: Report of Case and Analysis of Subcutaneous and Epidermal-Dermal Lipids by Chromatographic Methods,” Arch. Derm., 97:372-80, 1968. |
Koska, J. et al., “Endocrine Regulation of Subcutaneous Fat Metabolism During Cold Exposure in Humans,” Ann N.Y. Acad, Sci., 967:500-05, 2002. |
Kundu et al., “Breath acetone analyzer: diagnostic tool to monitor dietary fat loss,” Clin Chem, 1993, pp. 87-92, vol. 39, issue (1). |
Kundu et al., “Novel solid-phase assay of ketone bodies in urine,” Clin Chem, 1991, pp. 15659, vol. 37—issue (9). |
Kuroda et al., “Thermal distribution of radio-frequency inductive hyperthermia using an inductive aperture-type applicator: evaluation of the effect of tumour size and depth,” Med Biol Eng Comput, 1999, pp. 285-90, vol. 37—issue (3). |
Laugier, et al., “In Vivo Results with a New Device for Ultrasonic Monitoring of Pig Skin Cryosurgery: The Echographic Cryprobe,” The society for Investigative Dermatology, Inc., vol. 111(2), Aug. 1998. |
Levchenko, et al., “Effect of dehydration on lipid metabolism,” WMJ, 1978, pp. 95-7, vol. 50—issue (1). |
Lidagoster, MD et al., “Comparison of Autologous Fat Transfer in Fresh, Refridgerated, and Frozen Specimens: An Animal Model Presented,” at the 16th Annual Meeting of the Northeastern Society of Plastic Surgeons: Burlington, VT, 1999, pp. 512-515. |
Liu, A.Y.C. et al., “Transient Cold Shock Induces the Heat Shock Response upon Recovery at 37 C in Human Cells,” J. Biol. Chem., May 20, 1994, 269(20), 14768-14775. |
Lvova, “Lipid levels and lipid peroxidation in frog tissues during hypothermia and hibernation,” WMJ, 1990, pp. 65-70, vol. 62—issue (1). |
Maize, J.C., “Panniculitis,” Cutaneous Pathology, Chapter 13:327-344, 1998. |
Malcolm, G. et al., “Fatty Acid Composition of Adipose Tissue in Humans: Differences between Subcutaneous Sites,” Am J Clin. Nutr., 50(2):288-91, 1989. |
Merrill, Tom, “A Chill to the Heart: A System to Deliver Local Hypothermia Could One Day Improve the Lives of Heart-Attack Patients,” Mechanical Engineering Magazine, Oct. 2010 (10 pages). |
Moschella, S.L. et al., “Diseases of the Subcutaneous Tissue,” Derm., Section 2:1169-1181, 1985. |
Murphy, J.V. et al., “Frostbite: Pathogensis and Treatment,” The Journal of Trauma: Injury, Infection, and Critical Care, 48(1):171-178, 2000. |
Nagao et al., “Dietary diacylglycerol suppresses accumulation of body fat compared to triacylglycerol in men a double-blind controlled trial,” J Nutr, 2000, pp. 792-7, vol. 130—issue (4). |
Nagore et al., “Lipoatrophia semicircularis—a traumatic panniculitis: Report of seven cases and review of the literature,” Journal of the American Academy of Dermatology, Nov. 1998, 39:879-81. |
Nielsen, “Thermoregulation in Rest and Exercise,” Acta Phys Scan Supp, 1969, pp. 6-74, vol. 323. |
Nishikawa, “Ultrastructural Changes and Lipid Peroxidation in Rat Adipomusculocutaneous Flap Isotransplants after Normothermic Storage and Reperfusion,” Transplantation, 1992, 54, 795-801. |
Non-Final Office Action; U.S. Appl. No. 10/391,221; dated Jul. 22, 2005, 6 pages. |
Non-Final Office Action; U.S. Appl. No. 10/391,221; dated Jan. 25, 2006, 6 pages. |
Non-Final Office Action; U.S. Appl. No. 10/391,221; dated May 30, 2007, 8 pages. |
Non-Final Office Action; U.S. Appl. No. 11/016,196; dated Sep. 25, 2009, 8 pages. |
Non-Final Office Action; U.S. Appl. No. 11/016,196; dated Apr. 22, 2008, 11 pages. |
Non-Final Office Action; U.S. Appl. No. 11/359,092; dated Nov. 19, 2009, 13 pages. |
Non-Final Office Action; U.S. Appl. No. 11/435,502; dated Jul. 17, 2009, 10 pages. |
Non-Final Office Action; U.S. Appl. No. 11/528,225; dated Apr. 12, 2010, 11 pages. |
Non-Final Office Action; U.S. Appl. No. 11/558,046; dated Jul. 12, 2010, 14 pages. |
Non-Final Office Action; U.S. Appl. No. 11/741,271; dated Jul. 12, 2010, 9 pages. |
Non-Final Office Action; U.S. Appl. No. 12/942,852; dated Jun. 30, 2011, 10 pages. |
Non-Final Office Action; U.S. Appl. No. 11/528,225; dated Aug. 3, 2011, 13 pages. |
Non-Final Office Action; U.S. Appl. No. 12/565,613; dated Sep. 23, 2011, 55 pages. |
Pease, “An Integrated Probe for Magnetic Resonance Imaging Monitored Skin Cryosurgery,” Journal of Biomedical Engineering 117, 59-63, (1995). |
Pech, “Attenuation values, volume changes and artifacts in tissue due to freezing,” Acta Radiologica 6, 779-782 (1987). |
Peterson et al., “Bilateral Fat Necrosis of the Scrotum, Urology Service, Department of Surgery, Dermatology Service, Department of Medicine and Department of Pediatrics,” Letterman Army Medical Center, Journal of Urology, 1976, pp. 825-826, vol. 116, The Williams & Wilkins Co. |
Phinney, S.D. et al., “Human Subcutaneous Adipose Tissue Shows Site-Specific Differences in Fatty Acid Composition,” Am J. Clin. Nutr., 60:725-29, 1994. |
Rabi, “Metabolic adaptations in brown adipose tissue of the hamster in extreme ambient temperatures,” American Journal of Physiology 231, 153-160 (1976). |
Renold, A.E., “Adipose Tissue,” Handbook of Physiology, Chapter 15:170-76, 1965. |
Rubinsky, “Cryosurgery: advances in the application of low temperatures to medicine,” Int. J. Refrig. 190-199 (1991). |
Schoning, et al., “Experimental Frostbite: Freezing Times, Rewarming Times, and Lowest Temperatures of Pig Skin Exposed to Chilled Air,” Cryobiology, 1990, pp. 189-193, 27. |
Shephard, “Adaptation to Exercise in the Cold,” Sports Medicine, 1985, 2:59-71. |
Wang et al., “Cryopreservation of cell/hydrogel constructs based on a new cell-assembling technique”, Sep. 5, 2009, 40 pages. |
Wharton et al., “Cold acclimation and cryoprotectants in a freeze-tolerant Antarctic nematode, Panagrolaimus davidi,” Mar. 7, 2000, 2 pages. |
Winkler et al., “Gene Transfer in Laboratory Fish: Model Organisms for the Analysis of Gene Function,” Transgenic Animals, 1997, pp. 387-395. |
Young, H.E. et al., “Isolation of Embryonic Chick Myosatellite and Pluripotent Stem Cells,” J. Tiss. Cult. Meth., 14:85-92, 1992. |
Aguilar et al., “Modeling Cryogenic Spray Temperature and Evaporation Rate Based on Single-Droplet Analysis”, Eighth International Conference on Liquid Atomization and Spray Systems, Pasadena, CA, USA, Jul. 2000, 7 pages. |
Alster, Tina et el. “Cellulite treatment using a novel combination radiofrequency, infrared light, and mechanical tissue manipulation device,” J. of Cosmetic and Laser Therapy, vol. 7, 2005, p. 81-85. |
Duck, Francis A., Physical Properties of Tissue, Academic Press Ltd., 1990, chapters 4 & 5, pp. 73-165. |
Fournier, Luc et al. “Lattice model for the kinetics of rupture of fluid bilayer membranes,” Physical Review, vol. 67, 2003, 051908-1-051908-11. |
Gabriel, S. et al., “The dielectric properties of biological tissue: II. Measurements in the frequency range 10 Hz to 20 GHz,” Phys. Medical Biology, vol. 41, 1996, p. 2251-2269. |
Isambert, Herve “Understanding the Electroporation of Cells and Artificial Bilayer Membranes,” Phys. Review Letters, vol. 80, 1998, pp. 3404-3707. |
Saleh, K.Y. et el. “Two-dimensional ultrasound phased array design for tissue ablation for treatment of benign hyperplasia,” Int. J. Hyperthermia, vol. 20, No. 1, Feb. 2004, p. 7-31. |
Zouboulis et al., “Current Developments and Users of Cryosurgery in the Treatment of Keloids and Herpertrophic Scars”, Wound Repair and Regeneration, vol. 10, No. 2, pp. 98-102, 2002. |
Ardevol, et al., “Cooling Rates of Tissue Samples During Freezing with Liquid Nitrogen”, Journal of Biochem and Biophysical Methods, 27, 1993, 77-86. |
Peterson, et al., “Bilateral Fat Necrosis of the Scrotum”, 116 Journal of Urology, 1976, 825-826. |
Schoning, et al., “Experimental Frostbite: Freezing Times, Rewarming Times, and Lowest Temperatures of Pig Skin Exposed to Chilled Air”, 27 Cryoboliogy, 1990, 189-193. |
Hernan, P. et al., “Study for the evaluation of the efficacy of Lipocryolysis (EEEL)”, Nov. 30, 2011. |
Hernan, R. P., “A Study to Evaluate the Action of Lipocryolysis”, 33(3) CryoLellers, 2012, pp. 176-180. |
Jalian, H. R. et al., “Cryolipolysis: A Historical Perspective and Current Clinical Practice”, 32(1) Semin. Cutan. Med. Surg., 2013, pp. 31-34. |
Zelickson, B. et al., “Cryolipolysis for Noninvasive Fat Cell Destruction: Initial Results from a Pig Model”, 35 Dermatol. Sug., 2009, pp. 1-9. |
Number | Date | Country | |
---|---|---|---|
20120239123 A1 | Sep 2012 | US |
Number | Date | Country | |
---|---|---|---|
61435944 | Jan 2011 | US |